As PET scan imaging of AD patients reveals that Aβ deposits and pathological tau accumulation occur during the prodromal phase of AD [26], it has been suggested that therapies that are targeting Aβ or pathological tau accumulation must be implemented decades before the appearance of the symptoms to be successful [26]. This evidence concerns the gene MAPT and Alzheimer disease.